259 related articles for article (PubMed ID: 38683232)
61. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
62. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
63. CAR T cell therapies for patients with multiple myeloma.
Mikkilineni L; Kochenderfer JN
Nat Rev Clin Oncol; 2021 Feb; 18(2):71-84. PubMed ID: 32978608
[TBL] [Abstract][Full Text] [Related]
64. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
65. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
66. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY
Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241
[TBL] [Abstract][Full Text] [Related]
67. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?
Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E
Expert Rev Hematol; 2024 Jul; 17(7):375-390. PubMed ID: 38770902
[TBL] [Abstract][Full Text] [Related]
68. A compound chimeric antigen receptor strategy for targeting multiple myeloma.
Chen KH; Wada M; Pinz KG; Liu H; Shuai X; Chen X; Yan LE; Petrov JC; Salman H; Senzel L; Leung ELH; Jiang X; Ma Y
Leukemia; 2018 Feb; 32(2):402-412. PubMed ID: 28951562
[TBL] [Abstract][Full Text] [Related]
69. Targeting B-cell maturation antigen in multiple myeloma.
Tai YT; Anderson KC
Immunotherapy; 2015; 7(11):1187-99. PubMed ID: 26370838
[TBL] [Abstract][Full Text] [Related]
70. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
71. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
72. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
[TBL] [Abstract][Full Text] [Related]
73. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
[TBL] [Abstract][Full Text] [Related]
74. Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.
Harush O; Asherie N; Kfir-Erenfeld S; Adler G; Barliya T; Assayag M; Gatt ME; Stepensky P; Cohen CJ
Haematologica; 2022 Oct; 107(10):2395-2407. PubMed ID: 35354252
[TBL] [Abstract][Full Text] [Related]
75. GPRC5D-Directed CAR Yields 100% Response Rate.
Cancer Discov; 2022 Aug; 12(8):OF3. PubMed ID: 35748592
[TBL] [Abstract][Full Text] [Related]
76. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
[TBL] [Abstract][Full Text] [Related]
77. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
[TBL] [Abstract][Full Text] [Related]
78. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
79. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
80. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]